Resonant Capital Advisors LLC Boosts Stock Holdings in Danaher Co. (NYSE:DHR)

Resonant Capital Advisors LLC grew its holdings in shares of Danaher Co. (NYSE:DHR) by 2.5% during the 4th quarter, HoldingsChannel reports. The firm owned 12,902 shares of the conglomerate’s stock after buying an additional 319 shares during the period. Resonant Capital Advisors LLC’s holdings in Danaher were worth $2,988,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. BKM Wealth Management LLC purchased a new stake in Danaher in the fourth quarter valued at $27,000. OFI Invest Asset Management acquired a new stake in shares of Danaher during the third quarter valued at about $30,000. First Capital Advisors Group LLC. purchased a new stake in shares of Danaher in the 2nd quarter valued at approximately $32,000. BOK Financial Private Wealth Inc. acquired a new stake in Danaher in the 3rd quarter valued at approximately $34,000. Finally, Rakuten Securities Inc. purchased a new stake in Danaher in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several research reports. Citigroup increased their target price on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Raymond James lifted their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. KeyCorp increased their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday. Finally, Barclays boosted their target price on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 10th. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $268.27.

Insider Buying and Selling at Danaher

In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock valued at $8,265,802 in the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.6 %

Shares of NYSE:DHR traded down $1.32 during trading on Friday, hitting $235.04. 1,367,008 shares of the company were exchanged, compared to its average volume of 2,709,515. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The stock has a market capitalization of $174.06 billion, a P/E ratio of 36.80, a PEG ratio of 3.64 and a beta of 0.83. The firm’s 50 day moving average price is $249.09 and its 200-day moving average price is $229.90.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business’s quarterly revenue was down 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.87 EPS. On average, research analysts predict that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.